<SEC-DOCUMENT>0000939767-24-000025.txt : 20240206
<SEC-HEADER>0000939767-24-000025.hdr.sgml : 20240206
<ACCEPTANCE-DATETIME>20240206162836
ACCESSION NUMBER:		0000939767-24-000025
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20240206
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240206
DATE AS OF CHANGE:		20240206

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EXELIXIS, INC.
		CENTRAL INDEX KEY:			0000939767
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				043257395
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1229

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30235
		FILM NUMBER:		24600658

	BUSINESS ADDRESS:	
		STREET 1:		1851 HARBOR BAY PARKWAY
		CITY:			ALAMEDA
		STATE:			CA
		ZIP:			94502
		BUSINESS PHONE:		6508377000

	MAIL ADDRESS:	
		STREET 1:		1851 HARBOR BAY PARKWAY
		CITY:			ALAMEDA
		STATE:			CA
		ZIP:			94502

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXELIXIS INC
		DATE OF NAME CHANGE:	20000207

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXELIXIS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20000106
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>exel-20240206.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>exel-20240206</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-month-day-year" id="f-21">2/6/2024</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-22">0000939767</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-23">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="exel-20240206.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-06</xbrli:startDate><xbrli:endDate>2024-02-06</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i38032eda110f4c279316960ece66f772_1"></div><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:200.25pt"><tr><td style="width:1.0pt"/><td style="width:108.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:20pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:100%">FORM</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CURRENT REPORT </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 13 OR 15(d) OF THE </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES EXCHANGE ACT OF 1934 </span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">February 6, 2024</ix:nonNumeric></span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:200.25pt"><tr><td style="width:1.0pt"/><td style="width:198.25pt"/><td style="width:1.0pt"/></tr><tr style="height:47pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"><div style="text-align:center"><img src="exel-20240206_g1.jpg" alt="Exelixis_Logo_RGB_2023.jpg" style="height:47px;margin-bottom:5pt;vertical-align:text-bottom;width:177px"/></div></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">EXELIXIS, INC.</ix:nonNumeric></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Exact name of registrant as specified in its charter)</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.619%"><tr><td style="width:1.0%"/><td style="width:38.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.174%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:39.145%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">000-30235</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">04-3257395</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or Other Jurisdiction of Incorporation)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Commission File Number)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(IRS Employer Identification No.)</span></div></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">1851 Harbor Bay Parkway</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">Alameda</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-9">California</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">94502</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Address of principal executive offices) (Zip Code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">650</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">837-7000</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code) </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-13">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </span></div><div><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"/><td style="width:39.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.780%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.363%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 5.5pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 5.5pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock $.001 Par Value per Share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">EXEL</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). Emerging growth company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-20">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i38032eda110f4c279316960ece66f772_7"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02.  Results of Operations and Financial Condition.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;6, 2024, Exelixis, Inc. (Exelixis) issued a press release announcing its financial results for the quarter and full year ended December&#160;29, 2023, and providing a corporate update. A copy of such press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information in this report, including the exhibit hereto, shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this report and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Exelixis, whether made before or after the date hereof, regardless of any general incorporation language in such filing. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01.  Financial Statements and Exhibits.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(d) &#160;&#160;&#160;&#160;Exhibits.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"/><td style="width:8.914%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.429%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:51.967%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20231229exhibit991.htm">Press Release issued </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20231229exhibit991.htm">February</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20231229exhibit991.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20231229exhibit991.htm">6</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20231229exhibit991.htm">, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20231229exhibit991.htm">4</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20231229exhibit991.htm">.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i38032eda110f4c279316960ece66f772_10"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </span></div><div style="margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.428%"><tr><td style="width:1.0%"/><td style="width:26.608%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:54.526%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">E</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">XELIXIS, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NC.</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 6, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Jeffrey J. Hessekiel</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Jeffrey J. Hessekiel</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, General Counsel <br/>and Secretary</span></td></tr></table></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exel20231229exhibit991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i14032b0794eb4276a173c9dd47e7edbb_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-top:9pt"><img alt="image.jpg" src="image.jpg" style="height:49px;margin-bottom:5pt;vertical-align:text-bottom;width:182px"></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Contacts&#58;</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Chris Senner</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Chief Financial Officer</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Exelixis, Inc.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">650-837-7240</font></div><div style="text-align:right"><font style="color:#006ba6;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">csenner&#64;exelixis.com</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Susan Hubbard</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">EVP, Public Affairs &#38; Investor Relations</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Exelixis, Inc.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">650-837-8194</font></div><div style="text-align:right"><font style="color:#006ba6;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">shubbard&#64;exelixis.com</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">- Total Revenues of $480 million for the Fourth Quarter of 2023, $1,830&#160;million for the Fiscal Year 2023 -</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">- Cabozantinib Franchise Achieved $1,629&#160;million in U.S. Net Product Revenues for the Fiscal Year 2023, including $429&#160;million for the Fourth Quarter of 2023 -</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">- GAAP Diluted EPS of $0.27 for the Fourth Quarter of 2023, $0.65 for the Fiscal Year 2023 -</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">- Non-GAAP Diluted EPS of $0.33 for the Fourth Quarter of 2023, $0.90 for the Fiscal Year 2023 -</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">- Conference Call and Webcast Today at 5&#58;00 PM Eastern Time -</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ALAMEDA, Calif. &#8211; February&#160;6, 2024</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">-</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Exelixis, Inc. (Nasdaq&#58; EXEL) today reported financial results for the fourth quarter and fiscal year of 2023, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;Exelixis entered 2024 with significant momentum on the research, development, commercial and financial fronts,&#8221; said Michael M. Morrissey, Ph.D., President and Chief Executive Officer, Exelixis. &#8220;This year, we plan to advance our regulatory strategies for cabozantinib label expansions in neuroendocrine tumors and metastatic castration-resistant prostate cancer, both indications with high unmet medical need and the potential to drive revenue growth for the franchise for years to come. Positive data from the CABINET and CONTACT-02 studies give us confidence that cabozantinib has the potential to become an important option for clinicians treating patients with these forms of cancer. As we pursue these additional growth opportunities, we remain steadfast in our defense of cabozantinib&#8217;s intellectual property and anticipate a ruling on the second bench trial for our ongoing litigation with MSN Pharmaceuticals this spring.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dr. Morrissey continued&#58; &#8220;Our deep, differentiated and maturing pipeline is essential to our efforts to position Exelixis as a global biotech leader in oncology. Drawing on the cabozantinib experience and the integrated research, development and commercial capabilities highlighted at our recent R&#38;D Day, we are working to build multiple franchises across the Exelixis portfolio. As we concentrate our R&#38;D resources on our product development activities, we remain focused on accelerating zanzalintinib, XB002 and XL309 through clinical development, and filing Investigational New Drug applications for up to three development candidates in 2024. We believe the associated restructuring of our business, announced in January, will enable us to rapidly execute on our goals, maintain positive cash flow and deliver an innovative pipeline of biotherapeutics and small molecules for patients with cancer.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;- more - </font></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.899%"><tr><td style="width:1.0%"></td><td style="width:57.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exelixis Fourth Quarter and Fiscal Year 2023 Financial Results</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Page 2 of 10</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">February&#160;6, 2024</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Fourth Quarter and Fiscal Year 2023 Financial Results</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Total revenues </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">for the quarter and year ended December&#160;31, 2023 were $479.7&#160;million and $1,830.2&#160;million, respectively, as compared to $423.9&#160;million and $1,611.1&#160;million for the comparable periods in 2022. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total revenues for the quarter and year ended December&#160;31, 2023 included net product revenues of $429.3 million and $1,628.9 million, respectively, as compared to $377.4&#160;million and $1,401.2&#160;million for the comparable periods in 2022. The increases in net product revenues were primarily due to an increase in sales volume and an increase in average net selling price.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Collaboration revenues, composed of license revenues and collaboration services revenues, were $50.3&#160;million for the quarter ended December&#160;31, 2023, as compared to $46.5&#160;million for the comparable period in 2022. The increase was primarily due to higher royalty revenues for the sales of cabozantinib outside of the U.S. generated by Exelixis&#8217; collaboration partners, Ipsen Pharma SAS and Takeda Pharmaceutical Company Limited. Collaboration revenues were $201.3 million for the year ended December&#160;31, 2023, as compared to $209.8&#160;million for the comparable period in 2022. The decrease was primarily related to decreases in the recognition of milestone-related revenues and development cost reimbursements earned, partially offset by higher royalty revenues for the sales of cabozantinib outside of the U.S. generated by Exelixis&#8217; collaboration partners. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Research and development expenses</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> for the quarter ended December&#160;31, 2023 were $244.7&#160;million, as compared to $336.8&#160;million for the comparable period in 2022. The decrease in research and development expenses for the quarter was primarily related to a decrease in license and other collaboration costs, partially offset by increases in clinical trial costs, manufacturing costs to support Exelixis&#8217; development candidates and personnel expenses. Research and development expenses for the year ended December&#160;31, 2023 were $1,044.1&#160;million, as compared to $891.8&#160;million for the comparable period in 2022. The increase in research and development expenses for the year was primarily related to increases in manufacturing costs to support Exelixis&#8217; development candidates, personnel expenses and clinical trial costs, partially offset by lower license and other collaboration costs and lower stock-based compensation expense.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Selling, general and administrative expenses</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> for the quarter and year ended December&#160;31, 2023 were $131.4&#160;million and $542.7&#160;million, respectively, as compared to $119.3&#160;million and $459.9&#160;million for the comparable periods in 2022. The increases in selling, general and administrative expenses were primarily related to increases in personnel expenses, technology costs, facility expenses and legal and advisory fees.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Provision for (benefit from) income taxes </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">for the quarter and year ended December&#160;31, 2023 was $17.5 million and $49.8 million, respectively, as compared to $(1.3)&#160;million and $52.1&#160;million for the comparable periods in 2022, primarily due to an increase in pre-tax income.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">GAAP net income (loss) </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">for the quarter ended December&#160;31, 2023 was $85.5&#160;million, or $0.28 per share, basic and $0.27 per share, diluted, as compared to GAAP net loss of $(30.2)&#160;million, or $(0.09)&#160;per share, basic and diluted, for the comparable period in 2022. GAAP net income for the year ended December&#160;31, 2023 was $207.8&#160;million, or $0.65 per share, basic and diluted, as compared to GAAP net income of $182.3&#160;million, or $0.57 per share, basic and $0.56 per share, diluted, for the comparable period in 2022.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Non-GAAP net income (loss) </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">for the quarter ended December&#160;31, 2023 was $104.2&#160;million, or $0.34&#160;per share, basic and $0.33 per share, diluted, as compared to non-GAAP net loss of $(10.2)&#160;million, or $(0.03)&#160;per share, basic and diluted, for the comparable period in 2022. Non-GAAP net income for the year ended December&#160;31, 2023 was $289.4&#160;million, or $0.91 per share, basic and $0.90 per share, diluted, as compared to non-GAAP net income of $265.4&#160;million, or $0.83 per share, basic and $0.82 per share, diluted, for the comparable period 2022.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;- more - </font></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.899%"><tr><td style="width:1.0%"></td><td style="width:57.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exelixis Fourth Quarter and Fiscal Year 2023 Financial Results</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Page 3 of 10</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">February&#160;6, 2024</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Non-GAAP Financial Measures</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">To supplement Exelixis&#8217; financial results presented in accordance with U.S. Generally Accepted Accounting Principles (GAAP), Exelixis presents non-GAAP net income (and the related per share measures), which excludes from GAAP net income (and the related per share measures) stock-based compensation expense, adjusted for the related income tax effect for all periods presented. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exelixis believes that the presentation of these non-GAAP financial measures provides useful supplementary information to, and facilitates additional analysis by, investors. In particular, Exelixis believes that these non-GAAP financial measures, when considered together with its financial information prepared in accordance with GAAP, can enhance investors&#8217; and analysts&#8217; ability to meaningfully compare Exelixis&#8217; results from period to period, and to identify operating trends in Exelixis&#8217; business. Exelixis has excluded stock-based compensation expense, adjusted for the related income tax effect, because it is a non-cash item that may vary significantly from period to period as a result of changes not directly or immediately related to the operational performance for the periods presented. Exelixis also regularly uses these non-GAAP financial measures internally to understand, manage and evaluate its business and to make operating decisions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">These non-GAAP financial measures are in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. Exelixis encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP financial information and the reconciliation between these presentations, to more fully understand Exelixis&#8217; business. Reconciliations between GAAP and non-GAAP results are presented in the tables of this release.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">2024 Financial Guidance</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exelixis is maintaining the previously provided financial guidance for fiscal year 2024</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:56.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.480%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total revenues</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline"> </font></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$1.825 billion - $1.925 billion</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net product revenues </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$1.650 billion - $1.750 billion</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cost of goods sold</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4% - 5% of net product revenues</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Research and development expenses </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">(3)</font></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$925 million - $975 million</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Selling, general and administrative expenses </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">(4)</font></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$425 million - $475 million</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Effective tax rate</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">20% - 22%</font></div></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">____________________</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 financial guidance excludes expenses related to the restructuring plan announced in January 2024.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Exelixis&#8217; 2024 net product revenues guidance range includes the impact of a U.S. wholesale acquisition cost increase of 2.2% for both CABOMETYX and COMETRIQ effective on January 1, 2024.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Includes $40 million of non-cash stock-based compensation expense.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(4)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Includes $60 million of non-cash stock-based compensation expense.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;- more - </font></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.899%"><tr><td style="width:1.0%"></td><td style="width:57.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exelixis Fourth Quarter and Fiscal Year 2023 Financial Results</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Page 4 of 10</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">February&#160;6, 2024</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Cabozantinib Highlights</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cabozantinib Franchise Net Product Revenues and Royalties. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net product revenues generated by the cabozantinib franchise in the U.S. were $429.3&#160;million during the fourth quarter of 2023, with net product revenues of $427.7&#160;million from CABOMETYX&#174; (cabozantinib) and $1.6&#160;million from COMETRIQ&#174; (cabozantinib). For the year ended December&#160;31, 2023, net product revenues generated by the cabozantinib franchise in the U.S. were $1,628.9&#160;million, with net product revenues of $1,614.9&#160;million from CABOMETYX and $13.9&#160;million from COMETRIQ. In 2023, global cabozantinib franchise net product revenues generated by Exelixis and its partners exceeded $2.2 billion. Based upon cabozantinib-related net product revenues generated by Exelixis&#8217; collaboration partners during the quarter and year ended December&#160;31, 2023, Exelixis earned $40.7&#160;million and $148.5&#160;million, respectively, in royalty revenues.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Detailed Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors (NET) Presented at the 2023 European Society for Medical Oncology (ESMO) Congress.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> In October 2023, detailed results were presented from the phase 3 CABINET pivotal trial at the 2023 ESMO Congress. The CABINET trial evaluated cabozantinib versus placebo in two different cohorts of patients, those with pancreatic NET and those with extra-pancreatic NET. A statistically significant and clinically meaningful improvement in progression-free survival (PFS) was observed in those patients treated with cabozantinib in both cohorts. Adverse events were consistent with the known safety profile of cabozantinib. CABINET is sponsored by the National Cancer Institute and is led by The Alliance for Clinical Trials in Oncology (The Alliance). Previously, in August, Exelixis announced The Alliance&#8217;s independent Data and Safety Monitoring Board unanimously recommended to stop the trial early, unblind all patients and allow those on placebo to cross over to cabozantinib due to a dramatic improvement in efficacy. Exelixis is discussing these results with the U.S. Food and Drug Administration (FDA) to support a potential regulatory submission in 2024 and will provide an update when appropriate. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Detailed Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Presented at the American Society of Clinical Oncology 2024 Genitourinary Cancers Symposium (ASCO GU).</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> In January 2024, positive results from the primary PFS analysis in the global phase 3 CONTACT-02 pivotal trial were presented during an oral abstract session at ASCO GU. The results demonstrated a statistically significant improvement in PFS, as assessed by a blinded independent radiology committee (BIRC), for cabozantinib in combination with atezolizumab in the first 400 randomized patients in the intent-to-treat (PFS ITT) population and per protocol. A PFS benefit was observed across all subgroups of high-risk populations who have a poor prognosis and a high unmet need for additional treatment options, notably in patients with liver metastases or those who had received prior docetaxel chemotherapy. A statistically significant improvement in PFS was also observed by BIRC both in the ITT population (n&#61;507) and according to Prostate Cancer Clinical Trials Working Group 3 (PCWG3) criteria. An interim analysis for overall survival (OS), conducted at the time of the primary PFS analysis, demonstrated a trend favoring the combination of cabozantinib and atezolizumab. The study continues toward the next analysis of OS, which is anticipated in 2024. CONTACT-02 is evaluating cabozantinib in combination with atezolizumab compared with a second novel hormonal therapy (NHT) in patients with mCRPC and measurable extra-pelvic soft-tissue disease who have progressed on one prior NHT. The safety profile of the combination regimen was consistent with the known profiles of each single agent, and no new safety findings were identified. Exelixis will continue its discussions with the FDA on a potential regulatory path forward for the combination of cabozantinib and atezolizumab in mCRPC.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;- more - </font></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.899%"><tr><td style="width:1.0%"></td><td style="width:57.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exelixis Fourth Quarter and Fiscal Year 2023 Financial Results</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Page 5 of 10</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">February&#160;6, 2024</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Four-Year Follow-up Results from Phase 3 CheckMate -9ER Trial Evaluating CABOMETYX in Combination with Nivolumab (OPDIVO&#174;) in Previously Untreated Renal Cell Carcinoma (RCC) Presented at ASCO GU.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> In January 2024, four-year follow-up results from the CheckMate -9ER trial were featured in an oral presentation at ASCO GU. Results continued to show superior PFS and objective response rates (ORR) in patients treated with the combination of CABOMETYX and nivolumab over sunitinib, the comparator studied in the trial, regardless of risk classification. Superior OS was also observed in patients treated with the combination. The presentation included data showing health-related quality-of-life benefits with the combination as compared to sunitinib. No new safety concerns were identified in the follow-up analysis.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Pipeline Highlights</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Presentation of Encouraging Results from Expansion Cohort of Phase 1b&#47;2 STELLAR-001 Trial Evaluating Zanzalintinib in Patients with Advanced Kidney Cancer at the International Kidney Cancer Symposium (IKCS) 2023.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> In November 2023, Exelixis presented initial results from an expansion cohort of STELLAR-001 evaluating single-agent zanzalintinib in patients with previously treated clear cell renal cell carcinoma (ccRCC) at IKCS 2023. STELLAR-001 is a phase 1b&#47;2 trial evaluating zanzalintinib alone and in combination with atezolizumab in patients with locally advanced or metastatic solid tumors. In the ccRCC cohort of 32 patients, the findings demonstrated strong response rates and anti-tumor activity across the entire cohort, including in patients who had previously been treated with cabozantinib.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exelixis and Arcus Biosciences, Inc. Enter Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced RCC.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> In December 2023, Exelixis and Arcus Biosciences announced that the companies entered into a clinical trial collaboration for STELLAR-009, a phase 1b&#47;2 trial evaluating zanzalintinib in combination with AB521, an inhibitor of the transcription factor HIF-2&#9082;, in patients with advanced solid tumors, including ccRCC. The trial is divided into dose-escalation and expansion phases, and patient enrollment into dose-escalation cohorts is ongoing. Exelixis is sponsoring STELLAR-009, and Arcus is co-funding the study and providing AB521 for use in the trial.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Initiation of STELLAR-305 Phase 2&#47;3 Pivotal Trial Evaluating Zanzalintinib in Combination with Pembrolizumab in Patients with Previously Untreated Recurrent or Metastatic Head and Neck Cancer.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> In December 2023, Exelixis announced the initiation of STELLAR-305, a global, multicenter, randomized, double-blinded phase 2&#47;3 trial evaluating zanzalintinib in combination with pembrolizumab versus pembrolizumab alone in patients with previously untreated PD-L1-positive recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). The primary endpoints of the study are BIRC-assessed PFS and OS. Secondary endpoints include investigator-assessed PFS and ORR and duration of response as assessed by both BIRC and the investigator.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exelixis Provides Strategic Review of Biotherapeutics and Small Molecule Pipeline at its 2023 R&#38;D Day&#58; Science &#38; Strategy.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> In December 2023, Exelixis held its 2023 R&#38;D Day&#58; Science &#38; Strategy event in New York City. During the event, Exelixis speakers reviewed the strategy and progress of the company&#8217;s growing research and development pipeline, highlighted recent clinical updates, provided a comprehensive overview of its preclinical biotherapeutics and small molecule development candidates and elaborated on the company&#8217;s continued efforts to serve more patients with cancer and generate sustainable, long-term value for shareholders. The webcast replay of the event can be accessed via EXELRDDay.com and is also available at www.exelixis.com on the Event Calendar page under the Investors &#38; News heading.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;- more - </font></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.899%"><tr><td style="width:1.0%"></td><td style="width:57.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exelixis Fourth Quarter and Fiscal Year 2023 Financial Results</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Page 6 of 10</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">February&#160;6, 2024</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Corporate Highlights</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Appointments of Two New Board Members with Extensive Drug Development and Corporate Governance Expertise. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In January 2024, Exelixis announced the appointments of Mary C. Beckerle, Ph.D., and Gail Eckhardt, M.D., to the Exelixis Board of Directors, effective January 5, 2024. Dr. Beckerle is Chief Executive Officer of the Huntsman Cancer Institute and Distinguished Professor of Biological and Oncological Sciences at the University of Utah. Since 2006, she has had responsibility for the vision, strategic direction, and management of the University&#8217;s oncology programs, including research, care, education, and community outreach. She is also a noted cell biologist and cancer researcher. Dr. Eckhardt is Associate Dean of Experimental Therapeutics at Baylor College of Medicine and Associate Director of Translational Research at the College&#8217;s Dan L. Duncan Comprehensive Cancer Center. A recognized leader in translational medicine relative to oncology, she has focused her career on the preclinical and early clinical development of molecularly targeted therapies and combination regimens to treat colorectal and other gastrointestinal cancers.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Share Repurchase Program. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In January 2024, the Exelixis Board of Directors authorized the repurchase of up to an additional $450 million of the company&#8217;s common stock before the end of 2024. As of December 31, 2023, Exelixis completed the repurchase of 26.2 million shares of the company&#8217;s common stock for a total of $550 million, fulfilling its commitments under the prior share repurchase program announced in March 2023. Share repurchases under the 2024 program may be made from time to time through a variety of methods, which may include open market purchases, in block trades, accelerated share repurchase transactions, exchange transactions, or any combination of such methods. The timing and amount of any share repurchases under the share repurchase program will be based on a variety of factors, including ongoing assessments of the capital needs of the business, alternative investment opportunities, the market price of Exelixis&#8217; common stock and general market conditions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Announcement of Key Priorities and Anticipated Milestones for 2024.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> In January 2024, Exelixis announced its key priorities and anticipated milestones for 2024, including&#58; implementation of a corporate restructuring to prioritize the advancement of the company&#8217;s deep pipeline of clinical and near-clinical programs&#59; potential U.S. regulatory filings for cabozantinib in advanced NET and mCRPC indications&#59; the anticipated outcome of the cabozantinib Abbreviated New Drug Application litigation with MSN Pharmaceuticals in the first half of 2024&#59; expansion of zanzalintinib&#8217;s pivotal development program with priorities defined by emerging phase 1b&#47;2 data and potential clinical co-funding opportunities&#59; advancing JEWEL-101, the phase 1 study of XB002, a next-generation tissue factor-targeting antibody-drug conjugate (ADC), alone and in combination with immunotherapy in a variety of solid tumor settings with the goal of prioritizing sensitive tumor types for full development&#59; accelerating the phase 1 development of XL309, a potentially best-in-class small molecule inhibitor of USP1, as a potential therapy for tumors that have become refractory to PARP inhibitor (PARPi) therapy, including forms of ovarian, breast and prostate cancers, and pursuing potential PARPi combinations&#59; potentially filing three Investigational New Drug Applications for XB010 (5T4-MMAE ADC), XB628 (PD-L1-NKG2A bispecific antibody), and XL495 (small molecule PKMYT1 inhibitor) if preclinical data continue to be supportive&#59; and advancing two new programs to development candidate status, including a small molecule PLK4 inhibitor and an additional ADC. Exelixis presented the details of its key priorities and anticipated milestones at the 42</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">nd</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Annual J.P. Morgan Healthcare Conference. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Basis of Presentation</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exelixis has adopted a 52- or 53-week fiscal year that generally ends on the Friday closest to December&#160;31</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. For convenience, references in this press release as of and for the fiscal periods ended December&#160;29, 2023 and December&#160;30, 2022 are indicated as being as of and for the periods ended December&#160;31, 2023 and 2022, respectively.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;- more - </font></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.899%"><tr><td style="width:1.0%"></td><td style="width:57.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exelixis Fourth Quarter and Fiscal Year 2023 Financial Results</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Page 7 of 10</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">February&#160;6, 2024</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Conference Call and Webcast</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exelixis management will discuss the company&#8217;s financial results for the fourth quarter and fiscal year of 2023 and provide a general business update during a conference call beginning at 5&#58;00&#160;p.m. ET &#47; 2&#58;00&#160;p.m. PT today, Tuesday, February&#160;6, 2024.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">To access the conference call, please register using this </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">link</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Upon registration, a dial-in number and unique PIN will be provided to join the call. To access the live webcast link, log onto </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">www.exelixis.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and proceed to the Event Calendar page under the Investors &#38; News heading. A webcast replay of the conference call will also be archived on </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">www.exelixis.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> for one year.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">About Exelixis</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody-drug conjugates and other biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETYX&#174; (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">www.exelixis.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, follow &#64;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">ExelixisInc</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> on X (Twitter), like </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exelixis, Inc.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> on Facebook and follow </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exelixis</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> on LinkedIn.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Forward-Looking Statements</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This press release contains forward-looking statements, including, without limitation, statements related to&#58; Exelixis&#8217; 2024 plans to advance its regulatory strategies for cabozantinib label expansions into NET and mCRPC indications, both with the potential to drive revenue growth for the franchise for years to come, and Exelixis&#8217; confidence that cabozantinib has the potential to become an important treatment option for clinicians treating patients with these forms of cancer&#59; Exelixis&#8217; anticipation of a ruling in the second bench trial for its ongoing litigation with MSN Pharmaceuticals in the first half of 2024&#59; Exelixis&#8217; plans to </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">accelerate zanzalintinib, XB002 and XL309 through clinical development and to file Investigational New Drug applications for up to three development candidates in 2024 as part of its efforts to become a global biotech leader in oncology, as well as Exelixis&#8217; belief that its associated restructuring will enable the company to rapidly execute on its goals, maintain positive cash flow and deliver an innovative pipeline of biotherapeutics and small molecules for patients with cancer</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#59; Exelixis&#8217; 2024 financial guidance&#59; Exelixis&#8217; plans with respect to potential regulatory submissions for cabozantinib in advanced NET and mCRPC indications, including ongoing and future discussions with the FDA and related future updates&#59; Exelixis&#8217; anticipated timing of 2024 for the next analysis of OS from CONTACT-02&#59; Exelixis&#8217; plans to repurchase up to an additional </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$450 million</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> of its common stock before the end of 2024&#59; Exelixis&#8217; key priorities and anticipated milestones for 2024&#59; and Exelixis&#8217; scientific pursuit to create transformational treatments that give more patients hope for the future. Any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements and are based upon Exelixis&#8217; current plans, assumptions, beliefs, expectations, estimates and projections. Forward-looking statements involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of these risks and uncertainties, which include, without limitation&#58; the degree of market acceptance of CABOMETYX and other </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exelixis</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> products in the indications for which they are approved and in the territories where they are approved, and Exelixis&#8217; and its partners&#8217; ability to obtain or maintain coverage and reimbursement for these products&#59; </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;- more - </font></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.899%"><tr><td style="width:1.0%"></td><td style="width:57.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exelixis Fourth Quarter and Fiscal Year 2023 Financial Results</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Page 8 of 10</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">February&#160;6, 2024</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the effectiveness of CABOMETYX and other </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exelixis</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> products in comparison to competing products&#59; the level of costs associated with Exelixis&#8217; commercialization, research and development, in-licensing or acquisition of product candidates, and other activities&#59; Exelixis&#8217; ability to maintain and scale adequate sales, marketing, market access and product distribution capabilities for its products or to enter into and maintain agreements with third parties to do so&#59; the availability of data at the referenced times&#59; the potential failure of cabozantinib, zanzalintinib and other </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exelixis</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> product candidates, both alone and in combination with other therapies, to demonstrate safety and&#47;or efficacy in clinical testing&#59; uncertainties inherent in the drug discovery and product development process&#59; Exelixis&#8217; dependence on its relationships with its collaboration partners, including their pursuit of regulatory approvals for partnered compounds in new indications, their adherence to their obligations under relevant collaboration agreements and the level of their investment in the resources necessary to complete clinical trials or successfully commercialize partnered compounds in the territories where they are approved&#59; complexities and the unpredictability of the regulatory review and approval processes in the </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">U.S.</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and elsewhere&#59; Exelixis&#8217; continuing compliance with applicable legal and regulatory requirements&#59; unexpected concerns that may arise as a result of the occurrence of adverse safety events or additional data analyses of clinical trials evaluating cabozantinib and other </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exelixis</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> product candidates&#59; Exelixis&#8217; dependence on third-party vendors for the development, manufacture and supply of its products and product candidates&#59; Exelixis&#8217; ability to protect its intellectual property rights&#59; market competition, including the potential for competitors to obtain approval for generic versions of Exelixis&#8217; marketed products&#59; changes in economic and business conditions&#59; and other factors detailed from time to time under the caption &#8220;Risk Factors&#8221; in Exelixis&#8217; most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and in Exelixis&#8217; other future filings with the </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Securities and Exchange Commission</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. All forward-looking statements in this press release are based on information available to </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exelixis</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> as of the date of this press release, and </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exelixis</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> undertakes no obligation to update or revise any forward-looking statements contained herein, except as required by law.</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Exelixis, the Exelixis logo, CABOMETYX and COMETRIQ are registered trademarks of Exelixis, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">OPDIVO&#174; is a registered trademark of Bristol-Myers Squibb Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-see attached financial tables-</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;- more - </font></td></tr></table></div></div></div><div id="i14032b0794eb4276a173c9dd47e7edbb_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.899%"><tr><td style="width:1.0%"></td><td style="width:57.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exelixis Fourth Quarter and Fiscal Year 2023 Financial Results</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Page 9 of 10</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">February&#160;6, 2024</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EXELIXIS, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF INCOME </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(in thousands, except per share amounts)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(unaudited)</font></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:37.797%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.654%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.655%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended December 31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year Ended December 31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Revenues&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net product revenues</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">429,336&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">377,419&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,628,879&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,401,243&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">License revenues</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">45,229&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">38,079&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">178,635&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">162,056&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Collaboration services revenues</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5,087&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8,419&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">22,694&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">47,763&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total revenues</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">479,652&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">423,917&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,830,208&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,611,062&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cost of goods sold</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">21,753&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15,920&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">72,547&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">57,909&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">244,670&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">336,824&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,044,071&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">891,813&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Selling, general and administrative</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">131,441&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">119,251&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">542,705&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">459,856&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">397,864&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">471,995&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,659,323&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,409,578&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Income (loss) from operations</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">81,788&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(48,078)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">170,885&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">201,484&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Interest income</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">21,388&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16,988&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">86,543&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">33,065&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other income (expense), net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(137)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(337)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">93&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(197)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Income (loss) before income taxes</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">103,039&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(31,427)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">257,521&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">234,352&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Provision for (benefit from) income taxes</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17,521&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1,254)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">49,756&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">52,070&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;text-indent:18pt;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net income (loss)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">85,518&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(30,173)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">207,765&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">182,282&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net income (loss) per share&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Basic</font></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.28&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.09)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.65&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.57&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Diluted</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.27&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.09)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.65&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.56&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Basic</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">308,482&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">323,256&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">318,151&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">321,526&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Diluted&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">313,023&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">323,256&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">321,464&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">324,556&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">____________________</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The dilutive effect of shares related to employee stock plans are not included in the calculation of GAAP diluted loss per share in the fourth quarter of 2022 as the effect would be anti-dilutive. </font></div><div style="padding-left:18pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;- more - </font></td></tr></table></div></div></div><div id="i14032b0794eb4276a173c9dd47e7edbb_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.899%"><tr><td style="width:1.0%"></td><td style="width:57.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exelixis Fourth Quarter and Fiscal Year 2023 Financial Results</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Page 10 of 10</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">February&#160;6, 2024</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EXELIXIS, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">RECONCILIATION OF GAAP NET INCOME TO NON-GAAP NET INCOME </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(in thousands, except per share amounts)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(unaudited)</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:37.797%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.654%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.655%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended December 31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year Ended December 31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">GAAP net income (loss)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">85,518&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(30,173)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">207,765&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">182,282&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Adjustments&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Stock-based compensation - research and development expenses&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9,041&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10,464&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">34,320&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">45,350&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Stock-based compensation - selling, general and administrative expenses&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15,265&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15,392&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">72,025&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">62,224&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Income tax effect of the above adjustments</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(5,629)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(5,897)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(24,691)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(24,411)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Non-GAAP net income (loss)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">104,195&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(10,214)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">289,419&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">265,445&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">GAAP net income (loss) per share&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Basic</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.28&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.09)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.65&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.57&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Diluted&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</font></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.27&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.09)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.65&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.56&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Non-GAAP net income (loss) per share&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Basic</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.34&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.03)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.91&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.83&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Diluted </font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.33&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.03)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.90&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.82&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Basic</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">308,482&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">323,256&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">318,151&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">321,526&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Diluted&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">313,023&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">323,256&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">321,464&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">324,556&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">____________________</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Non-cash stock-based compensation expense used for GAAP reporting in accordance with Accounting Standards Codification Topic 718, </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Compensation&#8212;Stock Compensation</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The dilutive effect of shares related to employee stock plans are not included in the calculation of GAAP and Non-GAAP diluted loss per share in the fourth quarter of 2022 as the effect would be anti-dilutive. </font></div><div style="padding-left:18pt;text-indent:-18pt"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>exel-20240206.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:3d11cab9-1301-4c98-816b-4c3a9ab56261,g:91b89549-2068-4c65-9a75-f90a85fc5181-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exel="http://www.exelixis.com/20240206" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.exelixis.com/20240206">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20240206_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20240206_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.exelixis.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>exel-20240206_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:3d11cab9-1301-4c98-816b-4c3a9ab56261,g:91b89549-2068-4c65-9a75-f90a85fc5181-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_WrittenCommunications_4bc94fa4-180b-4b9c-8d8c-2fc991f00bdd_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_f7e175aa-9494-4df3-bd09-bda6a2bc94d3_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_873b0aef-55b6-4fb4-aa90-77fc7fa4b3f4_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_e7b0badb-0938-4e17-a7d9-71eb803146fd_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_59bc0a31-b905-4188-8947-eaebcc29ff89_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_d1ac2ef4-6472-4433-a126-b82b8dd3ac95_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_3abf50f6-3e13-4365-86fb-4901d4b652c7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_458bad9b-0bed-4ddd-b5ad-b9c9d8623409_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_56e91afa-d60a-4d50-85f4-7d694e06ca0d_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_3f345350-dfbd-4e79-8f3f-73542f596fe3_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_6c87e1a0-e88d-4f42-bb0e-561617352678_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_3934d3d0-2a56-4e92-bdd7-e0f1f4243469_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_7401f01e-bf57-44cd-934c-8b9edaa2b00a_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_ff13c0cb-d71b-41c2-b399-85d10e58f196_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_0b18192c-e32d-4ee1-a923-999226837764_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_cb026e0e-15ea-42cd-9d0a-306cde6bc0e5_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_069222f3-bff5-4bb5-889b-979e8a78db64_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_d0e6812d-65da-49bf-bcb4-2346366c2896_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_4df23489-212b-4708-bf20-f4e289730163_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_4758721e-3bbb-486d-9214-119d18f81403_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_4eae5551-2b5d-4651-a476-41941d70bac9_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_9a8715b7-1f4c-41a8-a49e-ef429677ff8c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_58f6947e-4166-4a13-8c88-2e226d6c89d9_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>exel-20240206_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:3d11cab9-1301-4c98-816b-4c3a9ab56261,g:91b89549-2068-4c65-9a75-f90a85fc5181-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.exelixis.com/role/CoverPage" xlink:type="simple" xlink:href="exel-20240206.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_0c2e6887-3cc7-4fd4-b4fa-efe599885b22" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_03fdf788-8141-4028-91b4-514a8a3a2861" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c2e6887-3cc7-4fd4-b4fa-efe599885b22" xlink:to="loc_dei_AmendmentFlag_03fdf788-8141-4028-91b4-514a8a3a2861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_62da7b0e-ede7-469f-bd17-de7cf056c1c2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c2e6887-3cc7-4fd4-b4fa-efe599885b22" xlink:to="loc_dei_DocumentPeriodEndDate_62da7b0e-ede7-469f-bd17-de7cf056c1c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_071b1367-9496-412a-909c-97035a44bd3b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c2e6887-3cc7-4fd4-b4fa-efe599885b22" xlink:to="loc_dei_EntityRegistrantName_071b1367-9496-412a-909c-97035a44bd3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_af801fcc-eb98-4b0f-aa12-80e6228e7c65" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c2e6887-3cc7-4fd4-b4fa-efe599885b22" xlink:to="loc_dei_EntityCentralIndexKey_af801fcc-eb98-4b0f-aa12-80e6228e7c65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_1a66a602-3faa-400d-9153-8cd6b75205ba" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c2e6887-3cc7-4fd4-b4fa-efe599885b22" xlink:to="loc_dei_EntityEmergingGrowthCompany_1a66a602-3faa-400d-9153-8cd6b75205ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_a330a8f2-7614-49dc-9c65-27bbf48c4cf3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c2e6887-3cc7-4fd4-b4fa-efe599885b22" xlink:to="loc_dei_Security12bTitle_a330a8f2-7614-49dc-9c65-27bbf48c4cf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_6ab282f0-db9a-4e7a-8d29-523cadc93b53" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c2e6887-3cc7-4fd4-b4fa-efe599885b22" xlink:to="loc_dei_TradingSymbol_6ab282f0-db9a-4e7a-8d29-523cadc93b53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_e09c01dc-2013-46e9-8a38-0b2f8db89de2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c2e6887-3cc7-4fd4-b4fa-efe599885b22" xlink:to="loc_dei_SecurityExchangeName_e09c01dc-2013-46e9-8a38-0b2f8db89de2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_c72b1e8f-a640-4122-8405-e945f8ac78c8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c2e6887-3cc7-4fd4-b4fa-efe599885b22" xlink:to="loc_dei_EntityFileNumber_c72b1e8f-a640-4122-8405-e945f8ac78c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_ed5f2864-d5f9-45c5-9e78-39583cfe3e80" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c2e6887-3cc7-4fd4-b4fa-efe599885b22" xlink:to="loc_dei_EntityIncorporationStateCountryCode_ed5f2864-d5f9-45c5-9e78-39583cfe3e80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_51e614ed-e33c-4845-91d5-bc6f2187ce6b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c2e6887-3cc7-4fd4-b4fa-efe599885b22" xlink:to="loc_dei_EntityTaxIdentificationNumber_51e614ed-e33c-4845-91d5-bc6f2187ce6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_c422c5f2-88fa-449c-9fb8-2769e900d58c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c2e6887-3cc7-4fd4-b4fa-efe599885b22" xlink:to="loc_dei_EntityAddressAddressLine1_c422c5f2-88fa-449c-9fb8-2769e900d58c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_10b05c82-2680-4e84-bbb9-e6af6f6fd164" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c2e6887-3cc7-4fd4-b4fa-efe599885b22" xlink:to="loc_dei_EntityAddressCityOrTown_10b05c82-2680-4e84-bbb9-e6af6f6fd164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_67fff39d-b10c-4e8f-ae97-6bcf984a0fc8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c2e6887-3cc7-4fd4-b4fa-efe599885b22" xlink:to="loc_dei_EntityAddressStateOrProvince_67fff39d-b10c-4e8f-ae97-6bcf984a0fc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_ab1cf645-4c83-460b-b9b4-fcb5fb1e365d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c2e6887-3cc7-4fd4-b4fa-efe599885b22" xlink:to="loc_dei_EntityAddressPostalZipCode_ab1cf645-4c83-460b-b9b4-fcb5fb1e365d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_8055e1fd-c014-4f37-a3f0-d08e809d7fa4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c2e6887-3cc7-4fd4-b4fa-efe599885b22" xlink:to="loc_dei_CityAreaCode_8055e1fd-c014-4f37-a3f0-d08e809d7fa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_5db76fe5-a27c-4854-b07b-9d572c2383a3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c2e6887-3cc7-4fd4-b4fa-efe599885b22" xlink:to="loc_dei_LocalPhoneNumber_5db76fe5-a27c-4854-b07b-9d572c2383a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_aef8491a-2a52-4ba7-9200-b5cdf17a87e7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c2e6887-3cc7-4fd4-b4fa-efe599885b22" xlink:to="loc_dei_WrittenCommunications_aef8491a-2a52-4ba7-9200-b5cdf17a87e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_06746168-185a-4c84-aa07-596b57db874d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c2e6887-3cc7-4fd4-b4fa-efe599885b22" xlink:to="loc_dei_SolicitingMaterial_06746168-185a-4c84-aa07-596b57db874d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_138d90aa-43e1-421d-934a-ce4339dfbab9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c2e6887-3cc7-4fd4-b4fa-efe599885b22" xlink:to="loc_dei_PreCommencementTenderOffer_138d90aa-43e1-421d-934a-ce4339dfbab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_b9ee4be8-2f77-4c97-8db9-66461970e07d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c2e6887-3cc7-4fd4-b4fa-efe599885b22" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_b9ee4be8-2f77-4c97-8db9-66461970e07d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_1cb7e44c-6bd3-44e3-8f68-0d2494d30a38" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0c2e6887-3cc7-4fd4-b4fa-efe599885b22" xlink:to="loc_dei_DocumentType_1cb7e44c-6bd3-44e3-8f68-0d2494d30a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>exel-20240206_g1.jpg
<TEXT>
begin 644 exel-20240206_g1.jpg
M_]C_X0TO17AI9@  34T *@    @ # $   ,    !#.0   $!  ,    !"?8
M  $"  ,    #    G@$&  ,    !  (   $2  ,    !  $   $5  ,    !
M  ,   $:  4    !    I $;  4    !    K $H  ,    !  (   $Q  (
M   A    M $R  (    4    U8=I  0    !    [    20 "  (  @ "OR
M   G$  *_(   "<0061O8F4@4&AO=&]S:&]P(#(S+C0@*$UA8VEN=&]S:"D
M,C R,CHP-SHR-2 Q.#HQ,#HR-@      !)    <    $,#(S,: !  ,    !
M  $  * "  0    !   $L* #  0    !   !1P         & 0,  P    $
M!@   1H !0    $   %R 1L !0    $   %Z 2@  P    $  @   @$ !
M  $   &" @( !     $   NE         $@    !    2     '_V/_M  Q!
M9&]B95]#30 !_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1
M%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,
M# P,# P,# P,# P,# P,# P,# P,# P,_\  $0@ + "@ P$B  (1 0,1 ?_=
M  0 "O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$!
M 0$          0 " P0%!@<("0H+$  !! $# @0"!0<&" 4###,!  (1 P0A
M$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$
MDU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:V
MQM;F]C='5V=WAY>GM\?7Y_<1  (" 0($! ,$!08'!P8%-0$  A$#(3$2!$%1
M87$B$P4R@9$4H;%"(\%2T? S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4
MHQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G
M-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\ ]5261]:>LW]%Z0_-QZVV7;V5L%D[
M 7NV[W[=KG;6_F[ERM/UT^N>16+<?IK+ZG3MLJQ<A[#!VNVOKM<WVN&U)3Z"
MDN6^K?7/K5U'J1IZGT\8N&VISG6FBZD[Y:*F,=D6.:_=^D^BQ4\WZX];Z+UO
M[%UFBA^'.X7T,L:YU+C#<FL/MNW.I_[48_T_]'_@?52GM4E1ZEUG Z=TQW4[
MK _'VAU1K(<;"[^991^;8Z[\S_TFL'ZI_6'ZQ==RK++Z<:GIU$BQ[&6%[K")
M9CU6/MV?HFG??;Z7_6_TOZ%*>L27"]3^N_7J^M9/3NG8E-HHL-5=9KLMM?L$
MV/VT6,_E.VMK^@AGZW?7H"?V1_[)Y7_I1*E6]\DL3J76.H]-^JW[4R*&#J#:
MJ3;1J*VVVNKJ>WZ3W;*K+?H>I_UW\]2^JG6,OK/21FYC:VVFVRN*@YK88[:W
M2Q]KO^DDIV4E4ZMG'IW2\O/#/4.+2^T5S&XL:7!N[\U8WU2Z_P!4ZY@YEF0V
MBN^BSTZ36UX9)8VP&UK[7N=[W?FO8ET4-Z>AMMKIJ?;8=M=;2][O -&YQ6-@
M?6FC,S&XSJ'4MM.VFQS@9/+6V,'\WN_K6*O@=?NRLM_3.K4UUB[=2=DB'_1=
M39N>_P#G?\&]G_HQ'P_JSB=/R?MMN0Y]>/+V!X:T-@'WVV?G^FW_ (M4SFRY
M90E@(]L2K+Q:2C_>XO\ N6\,&+%')'F ?<,;P\/JC+^[P_UOWW6S<RG"QG9%
MT[6P UHESG'VLJK;^=98[VL4L;[0:&')#1<1+VMX:3KZ8/YWI_0W_P"$6)@6
MOZYU0YKP1T_ ,8M9'TK2/YY_\ME?N_X+?7_PJIN^MO4'?7%O0ZZJ6X8M]%[W
M!QM,4G(<]K@]M;/?[/YNQ3XI^Y<Q\GRP_K?O3_[QKYL8Q 8S_.?-D_J7\N/_
M +]ZQ)<_]:OK77T&NNNNL7YEX<YC'.VL8QNANN=]+;N/L9_A5SK_ *W_ %WI
MK^UW=/:W&C<7.Q;FL#?WB_U2ZMO\NQ2TPOH22YSIOUHR.J]#?U"G%.,]C_2+
MW>^HF/YVA_Z+U*]WZ'U+/2KIM_G?T5-JU^E95^5ABV\#=);N @.C\X?2^B[]
M'N9^BLV>K3^AV)*?_]#KO\8G_B=/_ABG_JES71/KY^Q>F4]-^Q-O]$O/J&_9
M/J/??_-^C9MV^IM^FNE_QB$#ZNF?^Y%/_5+$^KGUXZ;TCH]'3[\>^VVDV%SZ
MQ66G?99<W;ZEU;_HV?N(]$=7H_JK]:'_ %A&4XXGV:O&+&ML%AL:]S]Y>P.]
M*GW5-;7N_P"-1_K3T3%ZQTM[;7LHNQP;<?*?H*W >[U'?]Q[&^V__MS^<KK5
M;HGUUZ?UKJ P,;'R*[#6ZW=8*]H:PL:9].VQW^%_=6#]=OK!;U'+'U<Z6/6!
ML%>0&'6VZ?;A-/T?3J=[\MW_ %NS]'3DI*>:P?M75;.G]&?E"G&]4MQ_4/LJ
M-ON>6:?I+'_S>(Q_^$M]%GI,N7KG3\#&Z=A586(S910W:P=_%SW'\ZRQ_OL?
M^>]</U?Z@/Q^@U6XLY'4J 7YC621<UWN>RAG[^-_VFV^^UG_  ]BUOJ/]:6]
M6QA@95@?GX[)%A,^M4/:V_\ XUGT,C_M[_"_HTH/*9/4_P!D?7+,ZEZ8N^SY
M-WZ,NV [VFG^<VV;?I_N+99_C0LL>VNKI8LM>X-96S(ESG..UK&-;C>YSEDG
MJ='2OKQE=0O:ZRNC)OW,KVEYWL=4W;ZCJV_2?^^NB_\ ',Z/_P!Q,K[J?_>A
M)3H_7O\ \2V9_6H_\_TH'^+S_P 3@_X^[_JDWUKS:\_ZC69U;75UY3,6YC7P
M'!K[L=[=^TN;^=^\L'ZL?7/IW1>E#!R*+[;!999NJ],MAYW-_G+:W?\ 125U
M>P^M7_B:ZI_X5M_ZDK!_Q9_T+J'_ (8;_P">ZT?*^LF)U_ZK=;LQ:K:6XU%C
M'^J&"2ZOU/;Z5EOT6E _Q9ZX/4"-1]I:)[3Z5:2NK:^MV#4RRK.8X-LM/IV-
M!@DM&ZNUG\JO;M=_UI4>I]<R\["HQK!Z8+0Z]YT;:02UEFG_ &G]F]__  G_
M !7Z2\^I_P!8^L.()_9N)^CW@Z.[O%?\N]WYS?\ M/Z?^D6A]8>D-RL%MF-6
M!=B#]&Q@YK'TZ&M;_)'Z)963%DR>_DQ'AQRTX?\ /</SR'\O6[./+CQ?=L6;
MU9(Z\1_R''_-Q/\ S?\ 9NAT[#JP<*K&J.YK!J_]YQ]S[/[;EP#?_P I?_H6
M?_;9=1]5.JMOH^P6.FRALT']ZK]W_K/T/^+]-<NT@_XS(&I^UG3OIBJ_R\X3
MQ1E#2-5P_NU^BYG-8YX\TXY-97?%^_Q?I.E]?_J_U#,R*>J853LEM=7HWU5B
M;&@.-E5U=?TK?=8_U/3_ $G\W_PGIY^%_C(ZK0X4Y^/5DN9HZ"ZB[3\Y];A8
MS?\ V*%O?6CZWY?0<ZBAN#ZN/8T.=D6/+&N))'H4/:VQOJLV[G>K_P"I%F]7
M^N_U>ZCTZRJ[I]M]KF$5LO96&M<1]/UVV/=7L_TE/Z53,+U'0^NX'6\0Y&&7
M--;MEM+P ^MT3M>UI<WW-^@]CO36DN(_Q98>0RC-SW@BC(]*NEYT%GI>KZEK
M/^#W7;-__&+MT$O_T?4,G$Q<NKT<JFO(JD.].UH>V1]%VUX<U5?V!T+_ ,K<
M3_MBO_R"OI)*:V+T[I^&YSL/%IQG/ #S56UA('&[TVMW*&/TCI.+:+L;"QZ+
M6SMLKJ8QPGZ4/8T.]RN))*4JC.D]+KR1EUX=#,D$N%[:F"S<X$/=ZH;OW/W.
MW*VDDII6=$Z-;8ZVW QK++#N>]U+"YQ/YSG.9N<Y1_8'0O\ RMQ/^V*__(*^
MDDI%?C8V32:,BIEU+HW56-#F':=S98^6^US55_8'0O\ RMQ/^V*__(*^DDIK
MLZ?@5XSL2O&J9BOD/H:QHK=N^GNJ V.W*EGU-HQV=)Z56S&MR]P J:&MJK_[
M4Y.RL-;^=L9_PUK%JH;?1]9^W;ZVUN_C=ME_I;OSMF[U=G_7$S(+@=:%>KOP
M_I4R8362)H2-^D'Y>/\ 0XN+]%A@X6/@XS,7';MKK'?DG\Y[_P"4Y'221AP\
M(X*X:]-;<*V?%QRX[X[/%Q?-Q?I6@9@X3+?79CU-NDGU QH=)^D=\;O=*9F!
M@UY+LNO&J9E6?3O:QHL=,?2M WN^BU6$DH\-'AK?7A[JGQV..]M.+LPMJJNK
M=5<QME;Q#F/ <TC^4URH-^K7U=:_U&],Q [F?19_Y%:22<M6    $ : !.DD
MDI__V?_M%2I0:&]T;W-H;W @,RXP #A"24T$!       *AP!6@ #&R5'' (
M  (  !P"!0 617AE;&EX:7-?3&]G;U]21T)?,C R,CA"24T$)0      $.Z*
M+VTF;HFD<OR1I?7(F<@X0DE-!#H      0L    0     0      "W!R:6YT
M3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90
M  !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE
M5$585    !0 0P!A &X ;P!N "  :0!8 #8 .  P #  ( !S &4 <@!I &4
M<P      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %,
M90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U
M:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M     !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#
M;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O
M;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
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M=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M    #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N
M9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P
M;&]N9P      .$))30/M       0 $@    !  $ 2     $  3A"24T$)@
M    #@             _@   .$))300-       $    'CA"24T$&0
M!    !XX0DE- _,       D           $ .$))32<0       *  $
M     3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H
M!@       0 R     0!:    !@       0 U     0 M    !@       3A"
M24T#^       <   _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@     _____________________________P/H   X0DE-! @      !
M   !   "0    D      .$))301$       0     @   D    )      #A"
M24T$'@      !      X0DE-!!H      V$    &              %'   $
ML    !8 10!X &4 ; !I '@ :0!S %\ 3 !O &< ;P!? %( 1P!" %\ ,@ P
M #( ,@    $                          0             $L    4<
M                     0                         0     0
M &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   4<
M    4F=H=&QO;F<   2P    !G-L:6-E<U9L3',    !3V)J8P    $
M  5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N
M97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
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M=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*
M    #     (_\        #A"24T$%       !     $X0DE-! P     "\$
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M!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $
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M    % !! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ #( ,  R #(
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M1T(                  /;6  $     TRU(4" @
M                                           18W!R=    5     S
M9&5S8P   80   !L=W1P=    ?     48FMP=    @0    4<EA96@   A@
M   49UA96@   BP    48EA96@   D     49&UN9    E0   !P9&UD9
M L0   "(=G5E9    TP   "&=FEE=P   ]0    D;'5M:0   _@    4;65A
M<P  ! P    D=&5C:   !#     ,<E120P  !#P   @,9U120P  !#P   @,
M8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T
M="U086-K87)D($-O;7!A;GD  &1E<V,         $G-21T(@245#-C$Y-C8M
M,BXQ               2<U)'0B!)14,V,3DV-BTR+C$
M                                                 %A96B
M  #S40 !     1;,6%E:(                     !865H@        ;Z(
M #CU   #D%A96B        !BF0  MX4  !C:6%E:(        "2@   /A
MML]D97-C         !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                9&5S8P         N245#(#8Q.38V
M+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M   N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S
M4D="                             &1E<V,         +%)E9F5R96YC
M92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M                                  !V:65W       3I/X %%\N !#/
M%  #[<P !!,+  -<G@    %865H@      !,"58 4    %<?YVUE87,
M     0                        */     G-I9R      0U)4(&-U<G8
M       $      4 "@ / !0 &0 > ", *  M #( -P [ $  10!* $\ 5 !9
M %X 8P!H &T <@!W 'P @0"& (L D "5 )H GP"D *D K@"R +< O #! ,8
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M^!GXJ/DX^<?Z5_KG^W?\!_R8_2G]NOY+_MS_;?___^X (4%D;V)E &1
M 0, $ ," P8               #_VP"$  (" @(" @(" @(# @(" P0# @(#
M! 4$! 0$! 4&!04%!04%!@8'!P@'!P8)"0H*"0D,# P,# P,# P,# P,# P!
M P,#!00%"08&"0T*"0H-#PX.#@X/#PP,# P,#P\,# P,# P/# P,# P,# P,
M# P,# P,# P,# P,# P,# P,#/_" !$( 4<$L ,!$0 "$0$#$0'_Q $/  $
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M P$! A$#$0   +_
M
M
M                                         #%O'^1Z4Y4Y!QL
M
M#X8^^+]SBOS_ *<F?>X_N],@   !T#X_VZT.BO0-K_H?S3O]L0
M                                                      !COXOW
M:W^D.^\4\>Y)JF.?_9^*?_<72<FN=]>@  #A_P WZJI///I2:7:/4TH>?==
M
M    #C\=ZB_.'I[I?R_J@#7,6F^@/.6:.4<3  &B)K-Z)]!]2^=].U_T/YIU
MS
M       C-P3L&N'I'OGX  28YUP"R#N_H0  0:ZG[BA7U=VS:5W]YSS?ROB
M
M     $,^L.UX)]2]Q@ #,_)^*VH^@O-X $:N#<_K=Z/[\D)S/@]F?>WGP
M
M   1[X9SBLOHGT&0 !*OL+KBPWN?HP 8LX_R.JOS[Z1VF6EM_HWS)D/[7P@
M
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M@  11M6ORU(I6C&J/S/LNPPSG$ROK:>=;YUB0!C:8K0O3M4.()YUOG*)
M%'&F4);5      VAZ@L=^U I0TR@;:H L4K>XW/0  #045:Y0VFH M I>V&F
M@%0&F=;MJ      #T69;9UB0(CVK0IIEJ!E5/I,QV     J?OG5_>GP$MHM?
M7EJ!7]TYW=$GKGLSX 2'YIP>S'O7SZ /QK?\*7WNN( %?737=\3.N^R_I.GM
MKIV9W9_4X \]VN,;Y@"VBFEG-+@ =3*5=<H9374   #X3-K:X&FF5(D59WIW
MX_8Z@<2BTVF@    \UFV.,4      =@/3OCON@<.>>W7'!$P!I+K<])[5N
M*NKTJBOG] )91:^G+7]@#SZ:XQIF      /U/33COW, JWOG5->@&54^DS'8
M    "@77*+$U EM%KZ\M0.'_ #?JJ(\W^H.K?/\ H ?$V6=Y] 2-YMP,   "
M)O779E?'3?=_U'=?J?*MW](>7]YKD!M#RT;8?0"VBFEG-+@#B#S[ZXQ]F
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M"VBFEG-+@8<F/-]KCK +#ZWN0STU             \TVV.-T 6KTO:530
M    #IB/._KEC&8 _0_, &?HGT&Y;<L   >?+7&-<P!8M6]Q>>@      JUO
MG51>@&54^DS'8    "@/7*+4U EM%KZ\M0 !MJ:5+^=/3../B?= )GQV_P!+
M3 [*ZM$+>KNV8,]3]Q$#<WI;CZ.\Q]^^Q\0  ; \M6V&L MHII9S2X'#'E[V
MP_, ^&?XF>M;R[K;.$3K           /--MCC= $Q*VEY%@  !VR)GK6P
M$=)CS]:X\<  #M9Z'LMLL1(   \^6N,:Y@"3\6G#6P   W4+%ZW  JUOG51>
M@&54^DS'8    "@/7*+4U EM%KZ\M0  ,+<6Y;5CY_\ 1WQ '*_H_/;KZ/\
M,.*N/\DK-Z)]!:( 2][)ZPGWW!TH  !L#RU;8:P"VBFEG-+@"B33*'-J@ #0
M=R)/UM+F+37K;(<2         /--MCC=      S/$^CK+8    5Z7I3/?/4
M#47NYZS"K8   #SY:XQKF     !S!ZB<=P *M;YU47H!E5/I,QV     H#UR
MBU-0);1:^O+4   5X=+]Z16Z^[& &;N5<1Q3Q[DO#_F_2!S7ZORV_P#I/RYS
M_P"S\0  &P/+5MAK +:*:6<TN ,,3'GKUQZR    :R:-;6P4TS;$@
M#S3;8XW0     ,\Q/HHRV    'YGF^UQQ', "4T6O[RU    'GRUQC7,
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M2J:        8IF//!KCU, Y(V1^0!E)/H?RU[A$@  >?+7&-<P!8M6]Q>>@
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M->0?L_# P=Q/F%7'07HL@#G/U_DMV]'^8.S?O^> !L#RU;8:P"VBFEG-+@
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M*GO/'I;9Y: ;O3.VOT7YER%]KX8V!Y:ML-8-9Z$<MI&Q( ZV53Z9UUVIQP
M !^Y976]L^>FX        *6=,^F3     'TR?$VB4OD6)$/[5KFO0 97B;?\
M]-8   /Q*YKTBG-=C(:2U//21$2*CM,\+S      [Y"SRFF88D 07M2!UZ@
M  #L$+%:WE)6P%36F>"YC<0E)%K**7_4 K^Z<[MB1USV;N;UM'[^\YYHY1Q,
M     8FX[R:(?6W:'7_Q_M S5RGB4R^SNJ1M"B_7+4<O"?5;S(K8  #I$Q!>
MU8BS6/MHQZC9&HY\S=$RVK:P2M\PQ(
M                    Q[\;[E2'G+TYMZ7L)[EZ/EAV)UH
M    !MSB#]CF#Z
M      5H=%^@8[\*YS++L7K2P7N3I
M                                          86XORVJ_S]Z.S5RCB=
MH_?WG/<7H
M                    !IB:I?/7I/JWS_I6P>B/-/9?W?/
M                                                           $
M9^"=@UW]+]Z6I^@O-V5>0\;
M                                   &USTJ(\W^H9U=M=-27YUU^
M
M         !#?K+M7KWXOW3I[:Z<
M                                        &!.(<TSSR[AFJ8
M
M
M                                                       __]H
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MC3+QB;C/,:P5*@C&,8<90ED55\!0*%0D++*BX*3& ("&F?3 PMW8#!G,'Z>
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M5U0ZG%827+'Q%YH3\@^].,B"L'2HMR^(^)H'R%#/LW4&ZAG,._@0XUAQ -V
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M<(JG4>['Z"5F^@E9OH)6:4T%628K'L#=@;L#";?0 =F [ 8&WR]@83L(B/\
MN=?5RI<&=X=X81V:2)7&#)_HV_\ NR>%OW^,:1Y8]Z/[$IN6_A<$ ;-*TN&6
M'[MV5V7V(B.S32M"J1J.DOE2)34YRGP_L2GM;]RA(:&>1#R6T!VCPWL2>O2N
MB+:J=4C),ECX<Z]B=1%K_&ZD66.X^Q0),@WD6   ?\:__]H " $#  $% /\
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M/WPXCO@N*Q$J"?OSOWF@3,8=]4!V8H[X?_1^!W "A^AN=(>=4I=LHANPAME
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M[F:WJ:?+\:$_?'3O7_)W&QC\F\T9"0T?"55IY%4SG+):S4[XJE87*5H-!E
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MR401)^UI-@%YHV\,(+8HZJ"P:[SF3H+N\@19CQ 7DX "LT7=Y-U;->[7L?P
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M0?=IE7*%1ZK#FMQ7Y$T>1-$'0D$9C[5>0VHB2E;M^"+VF]0KUJDL!54  "P
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M7L@Y9H\O4"*.ODA3&HJ7&V2IJ&QDF<\[.Q/XN0]NS?E>U9GHI%*&FN=)#5*
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M%;*2NJ9*(PPO*&(>0),S8#=YACV*2T%HK=G*Q=969(S Z_P]45P:"8C68)P
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M@RL#@58'80=1'(M69[))U=SL\XF@4DA94V20OAZB5"5/IX\VEHS19I-^BNT
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M0\C)GU5?/$SR:^[W.H6DM]LIY*JMJ7. 2*)2S,?Q#2\9LKPT?\QDW;=2-_\
MQZ./N8(O3"ZVZ6)]%<WYCI=[)]FGPH:20=S<JN(XX$'488B.ZYF;N=@;3 #
M#8.P)GNRTIDOF5XB+K%$I+U-MUL^H;6@.+CV.\.C0%3B",01SCD6[,U-ORT(
M_=;_ $*G^(H9".L&'.T9&^G;&'/I1W.W5*5E!<(4J**JC.*212*&1E/00<>1
M<OBLWN#H?;O[H\CB_P#7]N\1'(CX(T-/5V?+&7(Z:ZW]YXWA-XJIEWZ<Q[P'
M64U/TC4TN/\ ICE*TD:NR:T8@$J>D'FT$>5^)>:+%$-D%-=*DQ#M=5([I_\
M;H$BXN72I"@C>JZ:AG;7TEZ?0QS<7+K3*1@6HZ>AIV_ZDIP=!)G3.=\S81LC
MNM?/4Q#THG<QC\2Z    #  ; !R'D<[J("SMT ;=(KK?:1J7.7$5XKU?:>0
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D%$%P$,8@B50ZQ* JAR1@-8.BHBA$0!411@ !J  &P#_RV?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image.jpg
<TEXT>
begin 644 image.jpg
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M/'(4,C,97T8&1H\>C1T[=I@\'X\V;=F"F7-F8]28^S"4]:QR#1Z:CG&3)AI
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M#VGZC!D$W$@,26<Y*?P):<.1.&2XD9\A%'RY 2*_CT!BUL/(.N&Q? T.+4K
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MF#]_/LKY$A6HO/[ZZZBNKL;<N7-15%1DKLDSZ X=%TPLO?GFFXCBFS"!"I]
M5R1QB HVE!E/I[ ,<9A(G,)C&@N>8@K9/=:;*RDIF<K!MR[!)#\_O^,MWUGI
M=_,M.IPN3B2M@\2T5*305$^F0L53R>.9KQC&$<-\O/36"M.A*)-12JZR*$Z=
MBP52H0WI=%*UX_G77L5=?&,G,:YXQI5(D$MA&5/2AK!L!+OX1)JM8W'@P(&.
ML#(70_,I2T' F$CK(8%EBTNC,J53&,B)=(T2&5?B8"HU\YZ0DDK!4QVR7H,
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MS"C;?;P?] OU6[/SI!#FJW(\2D%Z B3VT8JJ2N33!%0^!ZLQ4P<[BA-DY5?
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M7AQ D1(QW\%KH=P5F)@.,=:3CI$"DSD/T9((^N4,Z"Q<Y+%3O72'U4:6PY'
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MW6[MM4HP8]H*WYF/"R8:Z^>Y]I.=-7NN60PI8C$=ECRHS-UDM8VU1BR'HZ[
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MTM5H#D& 5H0^6>$]LA'%CPS'P>RKT#+U+'AR?X&FW'[87? _./+10BHUW;.
MRX"8Z; EZV@ P_QWK!+E2JQ[6LR']F:T__@&]LR^%8<+KT5YX8VH*K@!;7F7
M(C#^5\"X\^CZ7(5-^3>B_.OY#%#,^+13/0,K(D5MY/*G8"*],!M!\RCK6& B
M4 AGF8C4P?K8XD6X8\#=9CI#$D$HGHIOON3'<+*X]:UAR7,$K12Y\]$$E[3A
MF1@U=AS&9V5A2E8.QHZ;0)!67TBLZ71-'S'"R)K55Z.SU MUP&HOY-=7.!N
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M#<WD,!@BLZ3/-#FCJ0],^NBTDD## 0R!!<%$4]>-7>* B?-+(*(S7>VC,Y.
6_Q]L!4#4?=TOGP    !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140040460674176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th"><div>Feb. 06, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb.  06,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EXELIXIS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000939767<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock $.001 Par Value per Share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EXEL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30235<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">04-3257395<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1851 Harbor Bay Parkway<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Alameda<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">837-7000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MXIKC$896%@G_JBI1H,VD-E#$_N#IY?6!*_::+2_ V,I"X=<8?$X&)X++*+A
MN^5A(*7_^[B!/\L0QF2VD0+U.%RDV^C<=L#HL.UL60D"W,"_01DP3-AJGF3B
MZ!RZ<EN+"]55]: L! 'NX7,9\Y ;6R@_P_16G%:6RAJ56IZS+3_NTS/%;D,8
M'@;K*]_3+F"/#;N"+ZM5=?YJ]&K)2NL/<)_^#]E4ZPS(:@'_WR$@*)T_N/(8
ML-BGE>NN)KY[^ZF*PST[3-J#^6=J=Z::Q&P%,MY=!QQ9'<ZZAX:1:7Z^7$H#
MI]7\<L,HC)%] 9ZOI#2GACVR%O]Q&/X#4$L#!!0    ( )&#1EB?H!OPL0(
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M/[&\UDX:?^:+X3]>?P%02P$"% ,4    " "1@T98!T%-8H$   "Q    $
M            @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( )&#
M1E@]@"]'[@   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E
M+GAM;%!+ 0(4 Q0    ( )&#1EB97)PC$ 8  )PG   3              "
M <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ D8-&6""@,5-0
M!   ?1   !@              ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q
M+GAM;%!+ 0(4 Q0    ( )&#1EB?H!OPL0(  .(,   -              "
M 9,,  !X;"]S='EL97,N>&UL4$L! A0#%     @ D8-&6)>*NQS     $P(
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9>&UL4$L%!@     )  D /@(  .L3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="exel-20240206.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="exel-20240206.htm">exel-20240206.htm</File>
    <File>exel-20240206.xsd</File>
    <File>exel-20240206_lab.xml</File>
    <File>exel-20240206_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>exel-20240206_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "exel-20240206.htm": {
   "nsprefix": "exel",
   "nsuri": "http://www.exelixis.com/20240206",
   "dts": {
    "inline": {
     "local": [
      "exel-20240206.htm"
     ]
    },
    "schema": {
     "local": [
      "exel-20240206.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "exel-20240206_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "exel-20240206_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2023": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 23
   },
   "report": {
    "R1": {
     "role": "http://www.exelixis.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentPeriodEndDate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exel-20240206.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentPeriodEndDate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exel-20240206.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0000939767-24-000025-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000939767-24-000025-xbrl.zip
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MY[)-,P\3RI#Z#HO[P_2W:[IC<Y?*I/MDI?\")MB:26B^#ZZ5GZ,[@2QY&ES
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M>"U$'YIR!L3QJ)0;G.?<^O3!H5$MJ$I'=*;#;N =R>/O@.;+Z!2&6F@6&_/
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M/;@GW>B>ZX%L6'/Z+V6I/Z]5_S]02P,$%     @ D8-&6"KSI"!O @  ?0<
M !$   !E>&5L+3(P,C0P,C V+GAS9,U5WV^;,!!^SU_A\3P##DT&J$FEM:HT
M*=NJKM7Z-ADXB%6PF6T:^M_7=H)2VF9KI#TL+SGNON]^'YR>]4V-'D J)OC"
M(W[H(>"Y*!BO%M[MS26.O;/E9'+Z >.[S]<K="'RK@&NT;D$JJ% &Z;72*\!
M_13RGCU0=%5370K98+QTM'/1/DI6K36:AM.3 39891H5A.0T2S")0H)/\B3&
M,9EG1HIH0K/9?#HG'ZLT(5F<S$X2/ WGL3'.9SBAGV:X3$(:S\I\1F+BG/8J
M5?D:&HI,:5REO5IX:ZW;- @VFXV_B7PAJV :AB2X^[KZX:#>#ELS?C]"]YFL
M!WP46'-&%0QPZ*$>P:V"]4SYN6@"6VYHLO40U5JRK--P:?IR 27M:KWP.OZ[
MHS4K&12FZ378MHX S\R:R@KT-]J :FD.[PBZG"!D>\&:5DB-^)O473-(DB1!
M;ZOST+9W*Y%3[5;B8#,<'EL1DRF.B-^KP@O>%7;LB'&E*<_AF-CF"0^\?Y'#
M?K+'Y3#PCL_!.5.0^Y5X" I@=G+1V^'5(;@5L!7&,2GG0CN^U>QT;<MX*;8*
MH[*)IT/VUU .Q_+J MY8$?>74IE+4?]EGX)6BA:D9J">7X]SL)90+CR[O7C8
MVE^M!-]D,D!>!1B/P)I-!%#F<ER]JWU!@PO]V!H7RLRAAFV+_N?Z:YH=6[^A
M0'UDX99X8^R(%0OO7)CW_Q6M3&)6?WO]Y?#KQ47<$P:O@]\"2L:9V[S0_0C"
M^T\&1HZ)+/4T>$EXX:I34'SG2R>_'/&.O(/\@9C3.N_JXWG[M [2=LJAD[M+
M"\:GMGU^=HY.L;WQY>0)4$L#!!0    ( )&#1EC5W1!EJJ<  (?8   4
M97AE;"TR,#(T,#(P-E]G,2YJ<&?L>P=44]W2Z$D"H7=$I(M4D=Y!BG0$I!<!
M@1 "1DH@"46Z#:4(%D1 I4D5$1#I4A0$!06E*R(J4D4ZTN&=!+!\UWO_>^]Z
MZ[VWUOLVY)S9LV?FS,R>/;OD9*MOZQ.-N'8 VA4 C(R @P  D /4$ " @1"$
M^@MX@6S#%-_!"Y0($SXI$/@V'H""%\8=&&2$[-F!P2N$#2 EP@"0"6'_ =^'
M"/W"*TFX OO!SR.(%!%F!C_=%]$ R0[])'CC _4B_%&NAP. (/WN_8@+QAG%
M8W(2@\?@3F*\>:2DQ61XA(P02+07 2,,2$E(22E)R"M)R?)(*BA)2BA)R0&$
M0G(% ,@(=PDI:<DTR$_]TZ"[SR4I2H/MPA!=8+O (; =6OBO]D&P/^V#!/YJ
M'Q3R0\99Z _95%D[\O1V;"3>M_JVO@'41)L<-8W ^A1 2ZP!+N'$]G[@/$!-
M3DY.04Y-04'-0$5)Q;"'CIJ:;@\K$],>)B96!FIBV;G]N4!HJ*AH:&GH:6GI
MF6EI:9D)%UKF;1:&?T? 5CW 0 X< M)@$%X R@"!,4"V!D##*+<:(6J@EJ00
M8MDQ$ 9&#0DIG(R<@I(*\M=&T$.PW49Z $("@4%)H*1D<')2&+4TV,@ (]G/
M*$EZQ!3!Q.MS1@K.?#6]6., WQZS)\[2,MBS;S3)^*^9SWR:1>)D63(>GA/0
MNF[AHOWT+EYN;X?E9]1<R?F&3M^A>1W!^,P+CVXT=GU9R"I]UCV\:.7J%Y&0
M7=;4,_)=7M?:S?_BS9SRYM[1)08 "@6U)2'J1 8GE26JL%^2D034P(>7B53J
MS%5F@@9/S-[,2/,Y?\*>O:9IO@>)DYGEAQ,4(!.0?=H!*G%WKXNVI1P>]?F'
M"O]< \&?*FR] ZAAQ&<R &K HD6";D]*29CV.-VKYH*R$S4WBHXK0X+*ID,'
M'OCU;'H-MW0N=GY-T79^'YK<.H'_]O"^_<6B)^^^%3[HE7_WJ91?]>RUX=J"
MQ?:"$[IY;(&IQJP5GGEMOMG1><K#&=F2;UD4"P=6C3.>&<M_C;,;J\%,GG"-
MXKZH?&%!JJFRJZ(!ZTY7]JTM9[,+N:&V$/8QQ"*G5-]TXH0;+ ??[*M\GZ[Y
M':?I_8OL5'5)*.Y;R ?K[1L"1:%Y&XC59[W8^P]7??+&N_2*)U$7IHHB756L
M5 =2,]"#(;4W-S +=>E' QMO4G5M5B].K/88'QOOBW\G5-1]PK5:M'2-I&_C
MD4W[L+*[^RJYVU?_WC3![[J;+X;#QK7RK)9>'#J6U:,49[1:L&;.&T&;]BY/
M[DUN0=F[B8F@T.L##_-%5[ER-OSGNVKO^<;4EG3H>"'=/;/[1:+.)?<AR\H-
MN-WKQOER4/SF^6Y<=SKFYAM4-*,-ONUYZ74([>TU_<IFT*)J"[#XFJB8X"(7
M-9W1?NRZG<,^_LM%[+9K#J-! RN%SB>8Y7/2R]Z-YWWO\^NU,_@P#;RI?(9T
M"D'?E9:L:$OO*NLLN\7QT66NI^_)^H?IKS;Y'WW7'CX<[%0JE>T1&]!_R\N]
M<,+H5LH6,!KVI"9U59*;;J)-T/C%FF<E;4C W'>RB$=RD*5^M]%5SRT@VJ+-
MHQ)%X72@G_'^8]NC:A\^;P&5&&K68EV^T^$A#>P-#1,Q==4-&YA!WQ*<\-,F
M/^W.TB*8+7^;S_>']_I7>FRFW9F+:U^?1+R@V<L@[AZ 5EIUVO3/69#? L[;
M)++4/?#53)[1-:Z7C#[.?;1#+25L[JUC]2952-C,O5NU98MD(3X8S0?W[")$
M%QR6R-@-S; <WRM42DL&)S>]GJD*K]V4G LNVBR?-MZ<+;S%V@B77A]]=7WU
MYMS0%E '=J_:8O[7$R'PJJ\/BD-1G]J0'-_N(]G3JT9#1*OCBE,_62MM 05;
MP(GQPF_^^._E;/)[E5E&BN27HC?,)OK7JYD?/5UE-+@]7F<KI52H&6:2PSRD
M$K<0/3"=F[CI=W$SNJO0?RS$0.7@>/G*X!OS4[WCQZV'$=$8&#YA"@J[.W^Q
M8U5L@VLD-.I52H%:>M^UU*W77^N:!#<%C3=9<S;S<">8OHY..B09&ZTQ818,
MVG,Q;U7O#H;-AUZ^Y;=Z*S1Y/*QI/VQB/'7MJO&&6>-JY>)0]D)LG*YQ'=>:
M9V:?_>HS5$Y(@OU ;59WW=C;M4L+NM9W5_,7T[< &QWS6,&W^4V'W#U8V-F6
MU$X'P6H.AG3+EDYM 9=U5SO?2 8V&P1Y!@E5<[#[S*6F%=0'U>B&O0]B_U:W
M^7X36]7M%;G8F[/X($U"LGA.I*CGJ[^-R#NVITU)"]^*!S^%^3IM^*T^P9BV
M<ELKV2R>*;*^PNI;-O[]D\P&][&<H+F!+<"N9 '_)3,G^<F:M65)SH+;,*5/
MC=G[,).U@W)K*<=SQ@^%S0?$A"T;A+ $&E8&CAK7-XWW62*<I5',\NYD87M5
MFN?O%V^N<:],VZM9KX:OAYZSK"BYVI5+NG+9Y2KNQ%20D-OT4-@[S]JUXUL
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M]H0.U);U3 _YO0W+JIXO\UKT"^MEDJ(ZTW,AL'IF\X840O::P/G+JT=6 K8
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ME]PUB3 H?@E(X"^1"VC\B/!M-<Q^!##17#C. XU$X:P\# E#$/+;<TB);2#
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M"7C"=[W,SNX$&$KXEI<9"RH(PJP$V&T;/D2DV8;5";"+IY<+"!-T]G;Q="'
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MWJ(MH^V@G:*CH..G.T+G0!=(ET!70M=.-TE/02] KTF/H ^EOT5?2=]+O\C
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M.W?',G%? IA.E3T.7OQ5WU\2*&LVLAU>L2A!J_>6^PK<S#A]O72*@><_'..
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M:I&GAN1-^C$OC'OK7GZE&#G)* 'OJ_;SSSFBSVO/E;1P'K"[2TX722LIX35
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M*"B;Q#+-;/"(/#(KFC;$K%^:=4H(TH.?&*IM#>)Q_U)EE87XLS*<?UA%-95
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M>B(Y=M<Q::(R]Y_=L3!)E,_+8F)T9HQ#6S,Y!1U(WY_E7]7^QPFI=W!? '\
M'PNF*#I=%%WBO)!F,"T]PM-_SF:0Q$B]F[=^M\']&[K?]A;^?9"?4@F.I^2A
MT6-_3HEAWQ:21.58Y@(=)^W6E"/1@F-- $_T)(N)<T$++BP6HV-/-*-F$!"
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M'U_ZN9@GO[BOC3M *3$A)+OVV1OFP6_I,\6J7S A5GB]H\6M&T41WM)6.7\
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MU42#<XLD-),)<[<('\RK'[OR]D^2_8M;/9O\8S:5QU2AN+VR3C_TZE0LP#2
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M>CP IZX201(<""_5]J9^=EJOY2%>65^'SG2NJUOA^68(,$1B$H9'7LJEC.]
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MY>[R%(86-]A9J=E9A_+AOS(@MB:&,,48/*U5GUTY^!J5IZ=F#+5+[& I@#T
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M_!^2OG**@!>1S)J;JDF3HE*W"[15S$:2'MP>/W>N$HP7S!#,M/8*?E]?A7]
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MG%JSID>U)9C<AMIOQU5WS[ROLOAMT#N.QJL&%52P??J1L;R,SNWIEMD]1_6
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ME[.717DYB<(PGJRM3U;F=UOVMW%C#2FED^;=!]-%UF5HW,+)'[^=?157:LY
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M6T6V/!^;'%?@@B4Z>RFVZ=JO0V\2#ET>[>)W$F!GK%[J:WL:37J= 6SJKMO
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M'Z#E)PY'EG%W.-L*[K'K$^\FXT;N?[Y]L7XE6W[W^-L7_P=02P,$%     @
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MS5;RW8^TME@?CA""LO7/=^TD"CW#V]P;OS=F7QF">L&:+YY#'.'UT*NGZ&T
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M">4Z9[ZR10+P I4E8$%PD$-G#WUQ^R5OV].;^D!^4?K2Y!TK*$)%=*RAI"%
M#+U7T+X41 ZZY1!Y% !R(PB"5M\HW#1J]6YO*;R[!Z7P?AP6.\=J2=;YMK);
M2^\LN*,%_MN=!^A?9-6OP'1>%D IX[4>8+SV<S%>&7+69;[^H*#2*? ,6DO9
M8Z"O#9D,1QH'W26O[+>7OK)OK,F1#[-CG3I3I\[4J3-UZDR=.E.A5(DZ=6:=
MU)EVG3KSRJDSE5;5'\JX2?3$E&G.N1G& =_FO)IEJ1+D''<I#+C@'U\LK9NA
MV]Z+1(*Y:0'X;"ITHOQMBO'](ER([IP=61:?X:/P%S_V*._^*@#5%HL#0K:'
M,-[7,O4 8NVP5!7>4Y4-RM^8Z+=L*I$#:]U/'&O"^%=*W0A%I=$F*SWJB@?U
MW4:,8?VA5*K5<JG;#BL_N!71$YC[KCQ3"1"W.KCY<)<25< 0BIHM*M$2QS95
MR%H44"7(3HE-H4$59H8L#ODH=C.D"G(. (T%6F*YR)=E&<*?+.)F:6F6"?^9
MA[BK.;8"$$U@PB8[$X%FQXI=,U/=M[CYAS>*A,<QGN-AR%L8=&-.$1]B#*P$
M37^5W3? 1%B )>R$+],P+@6&Z80^3G:N&%3DY>#9HO2SH?"H@TT)^_. ZP!T
M[EP9FPM,GE3-(K-(<Q!+E>AO JKHV\?:2" GAE5HHH8F"L!@)C]K<4E5D-),
M(8IU>I(O[6?E+@VK_<P87;D1EE^9A"@J6'$B/A48G)IS=H<TDZDQ!9"4'EF4
M9 FH4%8#P'[,42I%8$D'\$H,]07,F6+))&PJ'P3!S4H8$>G!7PG=B#]UF!)!
MD!:$N:$O:T8#6#D.B0H?XQ2L]PH\$KNP![K,L!#4IA@TZC^(1GYGNC$65R$]
M*API!$_-+SR#7+@:*3"QU4&7)7?>H]!$-D&&E *$I NBWP0)-(0M1U@S!<@D
M3PP()41G0$\E2P#AI MG:> QCL^0 @=:CS')+DPYGXIJX?>*IX7$(8PJ1B;L
M2^EA8KP.>SZ$]$A&@+IE$,B*IO2:Q+H\D"GBXR&/[CGW)$UF93H&^'QA6HO=
MI63X@(2XSBT?)NO3SO"GR3;5^<R Y_40W"4IJ:&X5AR$A8OAG6TFWG755BJD
M3U767V*'*&N+(?"(A@'_5Y6*=!T)%>/.\>,0B"]IZI!2]UB"A.1PMA/$LS?Z
MZ#5;W14.4^),18].H]WLE[AA\+X4J-YK[;]%.&'EGJ5/IJ?7]V9U6QMYLPZ:
M/:.SD3?KX>_:@X-G]Y%U]&:G_RS.7@5X$,T\L]RS/_G(-B1AH!OF/5 P"WW7
ML1G2_Z'\"KFI\,V:_AQ8X66=.>6.ZGP)PZO+)GUSV<16=CD]CJ.<,^K!10*Q
M[Q<B@D><FB_<GK&<0KYO-?M&EPUE(DR#P0>#](/U'9T[S$T7954PV\14>\9K
M7_AZKA%9S<LOS<L'73W/R[WT@RKS\FN"Z1@+5\#"&_OH/(&=V[D [C919H5B
MXIU_ ,%U_X& +:L67(R15X'L7OT*>;S88JOND_9^+=I?1[2C3C9-!?N@E_RS
MRF+]U?EKG4J0[6*U3LUJK\1JG3RK=9Z!U:0;J1R,.Z9>G5(\#1D-HVM!MCG_
MH]3V()R>A9X??,.W1^R&CFJ;8?QC&6GGTW8R.Y>'E]3;5\=W/(SPOF_@)\]U
MEL%*;N7_EOQOJ;OX%7??%9)]<R=^ZS$G_F/9QJ^(!(H>E81*DER:Y/(MQ+KS
M'2FI 7)9%TK1V?);0*M1);06XZZ$YM*F, G& TQW4.UO1,M69SHS+3*]39'D
M=3_Q78Y]'YAI_14[LJDM-99(*NNPO7K3^ <%VZC[]/'1A\OST]O_?)8-G^'O
MUV?_EFD<>.WX*;6(JHMO@V#:52*8,X7W[SOIB!IT#:BDFLV+U'<(99UJHNS@
MN5%6M]JMZX7J>J&Z7JBN%]K^^I"Z7FB=>J%.72_TRO5";Y]!F1M'^*LCAV!L
M<]'/DAGDY6,72R<JHG2XILY_#L\TXWM-':LT>R/72G!A(DHZC4BF!PNK5?3B
M-1::*=G">5$R,RR9$4;YV0^T@NT5^_M2;4%B\L)WO<XAV\ON<E\V>VT>E/U2
MFL>E/VR"#%^Y2V6YM;\Q^&2+VT)'@H?!@ZV).PN=JG( DK!8:&V< P85[(A3
MR9$Y2[;]^)G3>@M/3&I3#2?1X\4Y O1[HVFH%(PF^T#F4SQ#/T?FI4F[S=5?
M^7##RRPQKM5X*5.^)+IYH@E?WG6ZTU]HJI-OR(3]^0KM/G<ME?[=SR<\,AT7
MX'2=K8"ZFJ#SJIT,)[MR[B@7\Y9Z_IV*$AI$4$Z* L".Q,PWFUV9Y *+9#N.
MTZ]18#8R'U[DI[K=BJEN>_"R?1I#)^H:9-$<:6.G,0[_,CUVXUL.!Z2@3^U<
M#FR[E#.BV-[IS?GE/H[[I+F%S;>0U<B@EU;D W5*HK05E%7YANP?I\Z93(.;
M%0 _DX 7S19SX(!SIL>D=G;J1^)A5>ADY^4#J%YA'**/VN)#GV3;O9_.]0*&
MG-"@+A!9:C"1!F_U0UF>,\O@4(ZMRWS+"<_Y9YKLB-&8OI!T/C=7@);K*0E?
MI=5ZZ' -_#M1E.NDHRAQQM\(!TB%<7#GP"'9WM7'FWWJ3>,/L;^T*HC!727#
ME6C('7PCARSER99<L_+D321B !)GR/0*5U1D%.)XO60X'OOB^??8(WR$U C;
M&P&*BRV FPE6:)0<K.('Z85SH0KDCFGJ$Q".*JPBB1PR5SR+V#T"(944;ARK
M+IS$D51_F+) ]FFX)J^2>A"2:4?Q&"2-EA7^*E*1_6%F )_-9YS\D^P$1Q?B
MUF[$H<]]SXE\$M4??)P/&H/%Y$Q%\0G63$VG0EIC_U&PNT65DB!/K.S3X =#
M.(HM2H,5KDSQ@7\OD8@W@Z17K/RB*6H^#M^B.K ,*E5O.V8'YI3HKT!$'&=8
MFM8\4V &_P<+WXJ!LL2-0PW,)9LJ5-/=_]'WQ<@[&FYVE,G+@ WN?3PYVL_V
M634SXQBSXR_CX=0A*E:CSFA)&D\FRW4R(UBII-:<X=S# ,LLM[I8>J,;*!V)
MN?(E=.Q/AV"ZI[,=CR+^M^\Z?\=3DQXX3P>''J>#0Z^3P:%7:G"H9,N]Z?'U
MU7')Q70TA3-;F3L)N#]AS80A"<F_<&055&LPM",6#MG-'+OG._&4[1W='%^R
M7W[??[,K*QNDU-*Q=[G2:%%?AJTDYPRD;EI3+G5DJ9'.%K&7O\D*]Y]4]P"0
M/J4]#1$I%LY4$)P"X);@$3>=VI/-IR!1(Z%=F@_<,@4Q %NGLE SQ#<(&6LR
MDD1T>:02+S!M1S5KG4Z=*(*+9^_#V?7QOK8XOA9[8!=ISRS0'ME73A!&##"!
M<4;;GP*B[%3ZR8>PFAG0%OD-NKKHEF-GMZ ?S?P92A.ERF+K!CA=Y .1X%V+
MSZDFJKE+4<Z?1%$+4F@<^/&,[GGL;=\(G/!+9N40PYML8MYQ$F0^O6+L^:&T
M%LSLV%P:ETL-'M)N [1I@K<8.AM2]; Y=.=TF>=F'HI)BG*<+X;7R; CI8(V
M8=/H30?/,*,J8U ;.;:$!=MG B0@QBS.'U8T%DF H$.EY@F(@ X0N6I2,"$"
M8)X%^9[WPW<'K<.NWA.VJZA?EL,_BY*C>$__(>>$_H+ !P;9NSK^XY?V/MQI
M#M@XC@E'\$0=NS--F8MFU]Y11Y&,UG-YLX_C-SRTME*1%#G39-Y &:=J1::A
M#@9L9-[YB<F5)>+B2 ,Z<H:F!4/BN.)T>FPR+AP7\^""28\"RUW>J!XE1$MJ
MB*]J4MAI9L4&&G*II%^/VY+.@N(K-178 U"Z#'2]J2!403Q@>_QZN[](FR3Z
MY;AI+&NGD(%4<[E[!U=(Z(^ 3>%.!^4#- DQPD(QC]):Q?A5W^.2@N%E$G(+
MZF,1 Z \ $X]HM;E:JA<@"#,30LGB7MCS$T8)^-:/1^0<:_>.,)!V-Y8ZK>R
MM863:\- 2HE"*CD(E*:4#,_&#8#F0[-ERQ4> "=-R":"R#1?7)G"J*<]8J$.
MT=8AVCI$6X=HZQ!M':*M0[0B1-NM0[0[&:(5,T\;1.D???2%-<!@*'>13+CU
MY1R-CL;@]+K$/9*$E\I\(Q<.C3<$-6OO\NKD['\O1;"--.'4<\A^]Y0#]9J3
MPQ(;*AV;@>5X_M1D>]?'1?^(,MBKX<[ D&:#PD>C!)H+GHT")#.NBA&</58-
MJZ27(M?*+^NA4%A2FK-P?T[\^[1-EK#(P"88_BGS?C'VY-/P1.K;MW=Y?9VW
M1G(.[!(=.A]%]!*TDJ,TC'%*'FC76K;W>82=N\!R<S(MI/#,& D;@[KN<M&;
MGGP#EFN"XH_&=$2QP!MUELLR0WK5G0LC* ?*9.BHC=YFA!M2\82;;C1)(HU_
MQ28V^&OXHX;KC+AR>(3EX"FTF4^@@?WPLS81=N'B@;=@$R6.FX1VE$&[:Q'!
MAU)#KIP9Y?[N<EK(5:$_YZEL/X<DF).^IU_AIB'GY#'%C?!A(9%;PQ^^Z_0.
M#79S>_KIT]%U0]=;BU+Y_YG>W[#AU)=QE7,[)('4WQS;X\IAK)P\9Z+3H72U
MY1_)N)3/?CN^V2=%Z<VD\ 6ZW-) :+'/+;&6$V6[ZQ)T3<K+E@"V$@!G(9IQ
M"PE71X-<'>SO(F#S_IQ,=S0EERP7[P4+;[2 +C?ZJY5>;I9%UQL 'R$J )K;
M"[7<G.6QGXO"XB[S&S-== 91F&\%KW'!7^H+]Z:IB,1/O*<1.:2PR"^BD#IE
MBY XQ#-D0-DV<O%=GOJ#<OY!^-.'O1=N)]%R-7(:]!)FXA6&[5:EAQF70]%)
M<5-\H2:%.H(A=QKIWLT@94A]%9<%:W=-W&;,'83I46#%(?O@^*$% +*PJ>Z9
M9S5!"D4+SN3"/%^XUDY5:],%V;(8$?O0-5H/2!V@E3<3&2JSIR@R2@&4B5XG
M/9;IJO<<K-=#N)&,H:CPPNS*+ #1-9GR]$!;FZ/+^)C@K(EA:Q-GB,%RY>(%
M!O-"*W!FXNW 0_#=KV<?&\8/WPWTOG&H+3)^PO!9%L\R%W&YT*G$;BFZ+7I
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MKTNF@T&S/QAL0J7=7G/0[:U$I>LLVX8-==HO3/P/YN\2AEZ&_GNE]'_Z%92
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MXX@(9S1?OK_<?X>^/8<_)M'4_?G_ U!+ 0(4 Q0    ( )&#1E@HQ1-IY \
M *!M   1              "  0    !E>&5L+3(P,C0P,C V+FAT;5!+ 0(4
M Q0    ( )&#1E@J\Z0@;P(  'T'   1              "  1,0  !E>&5L
M+3(P,C0P,C V+GAS9%!+ 0(4 Q0    ( )&#1EC5W1!EJJ<  (?8   4
M          "  ;$2  !E>&5L+3(P,C0P,C V7V<Q+FIP9U!+ 0(4 Q0    (
M )&#1EA+_X.E< H  $M>   5              "  8VZ  !E>&5L+3(P,C0P
M,C V7VQA8BYX;6Q02P$"% ,4    " "1@T987W5!DZ\&  #J,   %0
M        @ $PQ0  97AE;"TR,#(T,#(P-E]P<F4N>&UL4$L! A0#%     @
MD8-&6&8VL.'!/0  A(P" !H              ( !$LP  &5X96PR,#(S,3(R
E.65X:&EB:70Y.3$N:'1M4$L%!@     &  8 C@$   L* 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>exel-20240206_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="exel-20240206.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-02-06</endDate>
        </period>
    </context>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-21">2024-02-06</dei:DocumentPeriodEndDate>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-22">0000939767</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-23">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2024-02-06</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">EXELIXIS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">000-30235</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">04-3257395</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">1851 Harbor Bay Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">Alameda</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">94502</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">837-7000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock $.001 Par Value per Share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">EXEL</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
